{
  "id": "625ebc98e764a53204000030",
  "type": "list",
  "question": "Please list the drugs associated with Drug-Induced Hypophosphatemia.",
  "ideal_answer": "Drug induced hypophosphatemia can occur with iron therapy as well a treatment with ferric carboxymaltose,  elotuzumab, cemiplimab, Temsirolimus,  capecitabine, panobinostat, bendamustine, ofatumumab, carboplatin and etoposide (BOCE)",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33638305",
    "http://www.ncbi.nlm.nih.gov/pubmed/33146741",
    "http://www.ncbi.nlm.nih.gov/pubmed/33051909",
    "http://www.ncbi.nlm.nih.gov/pubmed/26939882",
    "http://www.ncbi.nlm.nih.gov/pubmed/33237342",
    "http://www.ncbi.nlm.nih.gov/pubmed/2108845",
    "http://www.ncbi.nlm.nih.gov/pubmed/32337119",
    "http://www.ncbi.nlm.nih.gov/pubmed/33146052",
    "http://www.ncbi.nlm.nih.gov/pubmed/33563894",
    "http://www.ncbi.nlm.nih.gov/pubmed/31776845",
    "http://www.ncbi.nlm.nih.gov/pubmed/20356849",
    "http://www.ncbi.nlm.nih.gov/pubmed/34534708",
    "http://www.ncbi.nlm.nih.gov/pubmed/17117416",
    "http://www.ncbi.nlm.nih.gov/pubmed/32730387",
    "http://www.ncbi.nlm.nih.gov/pubmed/8069002",
    "http://www.ncbi.nlm.nih.gov/pubmed/27613487"
  ],
  "snippets": [
    {
      "text": "Contemporary intravenous iron formulations allow administration of high doses of elemental iron and enable correction of total iron deficit in one or two infusions. An important but underappreciated complication of certain formulations is hypophosphatemia caused by increased secretion of the phosphaturic hormone, fibroblast growth factor 23 (FGF23).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Persistent hypophosphatemia can occur with iron therapy and can cause debilitating diseases including myopathy, osteomalacia and fractures. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "review summarizes the current understanding of the iron-phosphate axis as well as complications of intravenous iron-induced hypophosphatemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33051909",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Administration of intravenous ferric carboxymaltose (FCM) for iron-deficient patients suffering heart failure with reduced ejection fraction (HFrEF) has been associated with transient hypophosphatemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33051909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biochemically relevant hypophosphatemia is common following a single dose of intravenous FCM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33051909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237342",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "requent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237342",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This retrospective study suggests that hypophosphatemia commonly occurs among MM patients receiving elotuzumab-containing therapies",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237342",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most common treatment-emergent adverse events (TEAEs) of any grade were contact dermatitis, rash, and viral upper respiratory tract infection (each n\u2009=\u20093, 23.1%). Five grade\u2009\u2265\u20093 TEAEs were reported in four patients: autoimmune colitis, dehydration, hyponatremia, hypophosphatemia, and muscular weakness.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33146741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most common non-hematologic grade 3-4 toxicities were neutropenic fever and hypophosphatemia. There were no treatment-related deaths. In conclusion, BOCE is a safe and effective outpatient salvage regimen for patients with RR NHL and serves as an effective bridge to stem cell transplantation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33146052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "orty-five patients were enrolled and 41 were evaluable\u00a0for dose-limiting toxicities (DLTs). The most common adverse events (AEs) were mucositis, fatigue, and thrombocytopenia. The most common grade 3/4 AEs were hypophosphatemia and anemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33638305",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Six dose-limiting toxicities were reported (mostly hematological); maximum tolerated dose of panobinostat (primary endpoint) was 10\u2009mg. Most common adverse events (AEs) were diarrhea (60%) and peripheral neuropathy (60%); all grade 1/2. Grade 3/4 AEs occurred in 80% of patients and included decreased neutrophil (45%), platelet (25%) and white blood cell (25%) counts, anemia (25%) and hypophosphatemia (25%). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33563894",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As treatment with imatinib could not be interrupted, hypophosphatemia and its symptoms resolved with oral phosphate intake.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other drugs such as immunomodulators or methotrexate have been also associated with hyponatremia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26939882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Alkylating agents have been linked with the occurrence of hyponatremia [due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)] and Fanconi's syndrome (hypophosphatemia, aminoaciduria, hypouricemia and/or glucosuria).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26939882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "catecholamines, beta-adrenergic agonists, sodium bicarbonate, and acetazolamide are commonly used therapeutic agents that could contribute significantly to the development of hypophosphatemia. Provision",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8069002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hypophosphatemia, defined as serum phosphate levels below 2.5\u00a0mg/dL (0.81\u00a0mmol/L), is frequently observed in the course of treatment with commonly used drugs, such as diuretics, bisphosphonates, antibiotics, insulin, and antacids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31776845",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17117416",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ypophosphatemia was significantly higher among COPD patients taking one or more drugs commonly used in COPD and known as negatively influencing renal phosphate handling: xanthine derivatives, corticosteroids, loop diuretics, and beta 2-adrenergic bronchodilators. Short-term administra",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2108845",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "phosphatemia, defined as serum phosphate levels below 2.5\u00a0mg/dL (0.81\u00a0mmol/L), is frequently observed in the course of treatment with commonly used drugs, such as diuretics, bisphosphonates, antibiotics, insulin, and antacids. Furthermor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31776845",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ns and patients should be aware of hypophosphatemia as a common complication of intravenous iron therapy and monitor serum phosphate concentrations in patients receiving repeated doses of specific intravenous iron formulations. Sympto",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ct, hypophosphatemia frequently develops in the course of treatment with drugs used in every-day clinical practice including diuretics and bisphosphonates. Prop",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356849",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ypophosphatemia induced by carboxymaltose iron and imatinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730387",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ere hypophosphatemia from daily marijuana use is a rare side-effect. A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32337119",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ceiving intravenous carboxymaltose iron in one occasion due to refractory anemia, she developed symptomatic hypophosphatemia. Urinary",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ith imatinib could not be interrupted, hypophosphatemia and its symptoms resolved with oral phosphate intake. These cases i",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Hypophosphatemia induced by carboxymaltose iron and imatinib. Report of two cases].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32730387",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In fact, hypophosphatemia frequently develops in the course of treatment with drugs used in every-day clinical practice including diuretics and bisphosphonates",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356849",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1\u00a0mmol/L), is frequently observed in the course of treatment with commonly used drugs, such as diuretics, bisphosphonates, antibiotics, insulin, and antacids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31776845",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Antacids, catecholamines, beta-adrenergic agonists, sodium bicarbonate, and acetazolamide are commonly used therapeutic agents that could contribute significantly to the development of hypophosphatemi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8069002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The administration of estrogens at high doses, streptozocin, azacitidine and suramin may induce hypophosphatemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26939882",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Tenofovir disoproxil fumarate (TDF) -containing regimens have been associated with nephrotoxicity and hypophosphatemia in HIV-infe",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613487",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report here that imatinib induces hypophosphatemia in a high proportion of our series of CML patients previously treated with interferon alpha, and that this previously unreported side effect is associated with response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17117416",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Ferric carboxymaltose, iron, elotuzumab, cemiplimab, bendamustine, BOCE, ofatumumab, carboplatin, etopside, Temsirolimus, capecitabine, panobinostat"
}